NasdaqGM - Nasdaq Real Time Price USD

Vanda Pharmaceuticals Inc. (VNDA)

4.3350

+0.0050

+(0.12%)

As of 12:12:50 PM EDT. Market Open.

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the approvability of tradipitant for gastroparesis. Rather than take accountability, FDA bureaucrats identify a new scapegoat: newly appointed Commissioner, Dr. Martin Makary, and reductions in force.

PR Newswire 20 hours ago

VNDA
+0.12%
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San Diego, California from April 5 through April 9, 2025.

PR Newswire 17 days ago

VNDA
+0.12%
High Growth Tech Stocks In US With Promising Potential

Over the last 7 days, the United States market has experienced a 3.0% drop, yet it remains up by 7.5% over the past year with earnings anticipated to grow by 14% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that exhibit strong innovation and adaptability to capitalize on these projected earnings growth trends.

Simply Wall St. 21 days ago

BIGC

VNDA
+0.12%
GCI
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysanti™ (milsaperidone) for the treatments of acute bipolar I disorder and schizophrenia. The NDA is supported by several clinical studies assessing the efficacy and safety of Bysanti™.

PR Newswire 24 days ago

VNDA
+0.12%
US High Growth Tech Stocks With Strong Potential

Over the last 7 days, the United States market has dropped 4.8%, yet it has risen by 15% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential through innovation and adaptability to leverage these market dynamics effectively.

Simply Wall St. last month

KNSA

FOLD
+0.21%
VNDA
+0.12%
February 2025 Penny Stocks To Keep An Eye On

As February 2025 unfolds, the U.S. stock market has shown signs of resilience with the S&P 500 and Nasdaq Composite inching higher after a four-day losing streak, despite ongoing concerns about the economic outlook. In this context, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their affordability and potential for growth. While traditionally viewed with caution, these stocks can offer unique opportunities when backed by strong...

Simply Wall St. last month

VNDA
+0.12%
RERE
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S).

PR Newswire last month

VNDA
+0.12%
Q4 2024 Vanda Pharmaceuticals Inc Earnings Call

Q4 2024 Vanda Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

VNDA
+0.12%
Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges

Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased competition and rising expenses.

GuruFocus.com 2 months ago

VNDA
+0.12%
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

VNDA
+0.12%
Vanda: Q4 Earnings Snapshot

WASHINGTON (AP) — Vanda Pharmaceuticals Inc. VNDA) on Thursday reported a loss of $4.9 million in its fourth quarter. On a per-share basis, the Washington-based company said it had a loss of 8 cents.

Associated Press Finance 2 months ago

VNDA
+0.12%
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2024.

PR Newswire 2 months ago

VNDA
+0.12%
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2024 on Thursday, February 13, 2025, after the market closes.

PR Newswire 2 months ago

VNDA
+0.12%
Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Vanda will pay AnaptysBio $10m upfront along with $5m for the current drug supply.

Pharmaceutical Technology 2 months ago

VNDA
+0.12%
ANAB
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supplyAnaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Anaptys

GlobeNewswire 2 months ago

VNDA
+0.12%
ANAB
BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

BioPharma Dive 2 months ago

BIOA

AKRO

VNDA
+0.12%
US Exchange Penny Stocks To Watch In January 2025

The U.S. stock market has recently experienced volatility, with the Nasdaq Composite and S&P 500 indices declining sharply due to concerns over China's advancements in artificial intelligence. Amidst these fluctuations, investors are increasingly exploring diverse opportunities, including penny stocks—an investment area that continues to intrigue despite its somewhat outdated terminology. These stocks often represent smaller or newer companies and can offer a blend of affordability and growth...

Simply Wall St. 2 months ago

VNDA
+0.12%
MNOV

ZNTL
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.

PR Newswire 2 months ago

VNDA
+0.12%
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) submitted by Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) for Tradipitant for symptoms in gastroparesis. The notice offers Vanda an opportunity to request a hearing on the matter. Also Read: Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst In September,

Benzinga 3 months ago

VNDA
+0.12%
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review.

PR Newswire 3 months ago

VNDA
+0.12%

Performance Overview

Return	VNDA	S&P 500 (^GSPC)
YTD	-9.50%	-7.34%
1-Year	-4.93%	+7.45%
3-Year	-60.37%	+27.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vanda Pharmaceuticals Inc. (VNDA)

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

High Growth Tech Stocks In US With Promising Potential

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

US High Growth Tech Stocks With Strong Potential

February 2025 Penny Stocks To Keep An Eye On

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Q4 2024 Vanda Pharmaceuticals Inc Earnings Call

Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Vanda: Q4 Earnings Snapshot

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

US Exchange Penny Stocks To Watch In January 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Performance Overview